The potential role of thromboxane and prostacyclin in endotoxic and septic shock.
The potential role of thromboxane (TxA2), a platelet aggregator and vasoconstrictor, and prostacyclin (PGI2) a platelet anti-aggregator and vasodilator, in endotoxic and septic shock was investigated. Early endotoxic shock in the rat is associated with marked elevations of plasma TxB2 (the stable metabolite of TxA2) and lesser increases in plasma 6-keto-PGF1 alpha (the stable metabolite of PGI2). Selective inhibition of TxA2 synthesis by several different chemical classes of Tx synthetase inhibitors was beneficial in endotoxic shock. In contrast, shock induced by acute intra-abdominal sepsis in the rat was characterized by high levels of plasma 6-keto-PGF1 alpha, which exceeded plasma TxA2 six- to eight fold at most time intervals studied. Tx synthetase inhibitors were not protective in this model of acute sepsis, but treatment with fatty acid cyclo-oxygenase inhibitors, an antibiotic (gentamicin), or reduction in arachidonic acid metabolism by essential fatty acid (EFA) deficiency significantly prolonged survival time. An important aspect of the latter study is that decreased arachidonic acid metabolism was an effective adjunct to antibiotic therapy. Conjoint administration of gentamicin in EFA-deficient rats or with indomethacin synergistically improved long-term survival, a result that was not evident with single treatment interventions. In addition to experimental studies, plasma TxB2 levels were measured during clinical sepsis. These studies demonstrated that plasma TxB2 levels were elevated tenfold in patients dying of septic shock compared with septic survivors or nonseptic controls. These composite experimental and clinical observations suggest that arachidonic acid metabolites play a role in the pathogenesis of endotoxic and septic shock.
D000818:Animals; D001095:Arachidonic Acids / Q000097:blood; D001241:Aspirin / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors; D011464:Epoprostenol / Q000032:analysis / Q000378:metabolism*; D005227:Fatty Acids / Q000172:deficiency; D005839:Gentamicins / Q000627:therapeutic use; D007052:Ibuprofen / Q000627:therapeutic use; D007093:Imidazoles / Q000627:therapeutic use; D008689:Methacrylates / Q000627:therapeutic use; D010538:Peritonitis / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D012772:Shock, Septic / Q000188:drug therapy / Q000378:metabolism*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D013931:Thromboxanes / Q000032:analysis / Q000378:metabolism*
D001095:Arachidonic Acids; D016861:Cyclooxygenase Inhibitors; D005227:Fatty Acids; D005839:Gentamicins; D007093:Imidazoles; D008689:Methacrylates; D013931:Thromboxanes; C029166:dazoxiben; C031517:2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid; C029899:imidazole; D011464:Epoprostenol; D013930:Thromboxane-A Synthase; D001241:Aspirin; D007052:Ibuprofen